Combination therapy for STK11-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your lung cancer must have a change in the STK11 gene, confirmed by a genetic test.
- Your cancer must have grown while you were on a checkpoint inhibitor like pembrolizumab, and your doctor thinks you can continue it.
- You should be physically able to take care of yourself (a score of 0 or 1 on a common activity scale).
- You must have measurable disease on scans (at least one tumor that can be seen and measured).
- You need adequate organ function (kidney, liver, blood counts) and a healthy heart (measured by an echocardiogram or similar).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new oral drug, JBI-802, alone or with pembrolizumab, for people with advanced non-small cell lung cancer that has a specific change in the STK11 gene. The goal is to see if this treatment can help shrink tumors or slow their growth.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.